Assessment shows comparative efficacy of AVT05 and reference product golimumab in RA, suggesting enhanced accessibility for patients.
Introduction: Golimumab is a safe and effective treatment for patients with RA. Biosimilars to the reference product (RP; Simponi) may make treatment more accessible.
No takes yet. Share an insight, caveat, or question.
Luque et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: